Tech Company Financing Transactions
CDR-Life Funding Round
JEITO, Omega Funds and RA Capital participated in a $76 million Series A capital raise for CDR-Life. The financing round was announced on 4/13/2022.
Transaction Overview
Company Name
Announced On
4/13/2022
Transaction Type
Venture Equity
Amount
$76,000,000
Round
Series A
Investors
Proceeds Purpose
Jeito chooses CDR-Life as its 10th investment and continues to build a strong and diversified portfolio of companies with breakthrough therapies in areas of unmet needs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Wagistrasse 27
Schlieren Zurich, CH-8952
Switzerland
Schlieren Zurich, CH-8952
Switzerland
Phone
Website
Email Address
Not Recorded
Overview
CDR-Life is a biotherapeutics company developing novel therapies harnessing the power of the immune system. Today's cancer immunotherapies are powerful but are not tumor targeted, which compromises both efficacy and safety. We are developing a next generation of highly tumor-selective immunotherapies to truly empower the immune system to eradicate malignant cells without the off-tumor-related limitations of current immunotherapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christian Leisner
Chief Financial Officer
Konstantin Schulthess
Chief Scientific Officer
Leonardo Borras
Chief Technical Officer
Rouven Erlenmeyer
Browse more venture capital transactions:
Prev: 4/13/2022: Raptor Maps venture capital transaction
Next: 4/13/2022: Treinta venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs